Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Gilles Avenard M.D. | Founder, CEO & Director | 361.67k | -- | 1951 |
| Ms. Sophie Lebel-Binay Ph.D. | Deputy CEO, Chief Scientific Officer & GM | 238.94k | -- | 1968 |
| Dr. Yannick Pletan M.D., M.Sc. | Deputy CEO, GM & Chief Medical Officer | 279.91k | -- | 1953 |
| Mr. Philippe Billiald Ph.D., Pharm.D. | Scientific Founder | -- | -- | -- |
| Ms. Martine Jandrot-Perrus M.D., Ph.D. | Scientific Founder | -- | -- | -- |
| Mr. Francois Guillet | Chief Financial Officer | -- | -- | -- |
| Mr. Elie Toledano | Head of Scientific Affairs & Business Intelligence | -- | -- | -- |
| Ms. Adeline Meilhoc | Head of Global Clinical Development | -- | -- | -- |
| Mr. Anouar Sari | Head of Clinical Operations | -- | -- | -- |
Acticor Biotech SAS
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 31
Description
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It's product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Phase 2/3 clinical trial for treatment of cerebrovascular accidents in emergency situations, as well as completed Phase 2 clinical trial for treating acute respiratory distress syndrome (covid-19). The company has collaboration agreement with the University of Birmingham for Phase 2b clinical trials of glenzocimab in treating heart attacks. The company was incorporated in 2013 and is headquartered in Paris, France.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available